Available Technological Offer
Recombinant chimeric antigen used for the prevention or treatment of infections caused by Anaplasma phagocytophilum.
Live attenuated vaccine incorporating a variant of the Rift Valley Fever virus obtained in the laboratory by serial passages in the presence of a mutagenic agent, that could be the basis of a new vaccine strain with safety parameters not previously described.